Against the backdrop of aging, chronic diseases, and a growing population, the healthcare system is going through a vital transformation. Healthcare is simply becoming increasingly individual-centric.

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

Russian defence export agency Rosoboronexport revealed details about the sensors integrated into Pantsir-S1M, which is the ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Dexcom (DXCM – Research Report). The ...

DexCom, Inc. DXCM reported fourth-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which missed the Zacks ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

The global glucose monitoring devices market was valued at USD 14.1 billion in 2023 and is expected to grow to USD 15.67 ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...